MYX (MYXFinance) experiences 40.7% volatility in 24 hours: High trading volume followed by a brief rebound and rapid decline
Bitget Pulse2026/04/19 04:42Volatility Brief
In the past 24 hours, the price of MYX peaked at $0.3057 and dropped to a low of $0.2173, with the current quote at $0.2173, resulting in a price range of 40.7%. The 24-hour trading volume surged significantly to about $57.41 million (CMC data) or $46.52 million (CoinGecko data), both exceeding its market cap (around $43.4 million-$63.4 million). Capital flows remained active, but were accompanied by an overall decline of -14% to -17%.
Brief Analysis of the Reasons for the Movement
- There have been no official announcements or major news events in the past 24 hours, but a spike in trading volume (several times higher than usual) drove the price to briefly rebound near $0.30 before quickly falling back. This may be attributed to speculative trading in leveraged perpetual contracts and the inflow of bullish capital.
- On-chain TVL remains at $16.96 million, with DEX trading volume around $3.3 million, and there are no records of significant whale transfers or alerts.
(Compared to the 109% surge on April 14-15, which was mainly driven by a 300% spike in trading volume and increased interest in holding positions that triggered a short squeeze, this time reflects a continuation of similar volatility.)
Market Perspectives and Outlook
The community's prevailing sentiment is cautious. Discussions on X platform have often attributed MYX's recent volatility to "manipulation and whale coordination," similar to the RAVE collapse case. There is concern about dumping risk after a pump; analysts warn that high-leverage funding rates and concentrated positions may lead to further liquidations, with high volatility likely persisting in the short term. Support is around $0.22.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
